ATE302191T1 - Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile - Google Patents

Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile

Info

Publication number
ATE302191T1
ATE302191T1 AT03724293T AT03724293T ATE302191T1 AT E302191 T1 ATE302191 T1 AT E302191T1 AT 03724293 T AT03724293 T AT 03724293T AT 03724293 T AT03724293 T AT 03724293T AT E302191 T1 ATE302191 T1 AT E302191T1
Authority
AT
Austria
Prior art keywords
quinole
carbonitriles
quinoline
substituted
producing
Prior art date
Application number
AT03724293T
Other languages
English (en)
Inventor
Diane Harris Boschelli
Yanong Daniel Wang
Steven Lawrence Johnson
Dan Maarten Berger
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE302191T1 publication Critical patent/ATE302191T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
AT03724293T 2002-04-30 2003-04-29 Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile ATE302191T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37645602P 2002-04-30 2002-04-30
PCT/US2003/013149 WO2003093241A1 (en) 2002-04-30 2003-04-29 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles

Publications (1)

Publication Number Publication Date
ATE302191T1 true ATE302191T1 (de) 2005-09-15

Family

ID=29401349

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03724293T ATE302191T1 (de) 2002-04-30 2003-04-29 Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile

Country Status (26)

Country Link
US (1) US6780996B2 (de)
EP (1) EP1499594B1 (de)
JP (1) JP2005529907A (de)
KR (1) KR20040106420A (de)
CN (1) CN100354263C (de)
AR (1) AR039776A1 (de)
AT (1) ATE302191T1 (de)
AU (1) AU2003231162B2 (de)
BR (1) BR0309712A (de)
CA (1) CA2483529A1 (de)
CO (1) CO5631435A2 (de)
CR (1) CR7511A (de)
DE (1) DE60301350T2 (de)
DK (1) DK1499594T3 (de)
EC (1) ECSP045406A (de)
ES (1) ES2243903T3 (de)
IL (1) IL164851A0 (de)
MX (1) MXPA04010664A (de)
NO (1) NO20044533L (de)
NZ (1) NZ536141A (de)
RU (1) RU2309149C2 (de)
SI (1) SI1499594T1 (de)
TW (1) TWI275390B (de)
UA (1) UA77799C2 (de)
WO (1) WO2003093241A1 (de)
ZA (1) ZA200409639B (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279795A1 (en) * 2002-10-04 2004-05-04 Caritas St.Elisabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization
US20040229880A1 (en) * 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
KR20060118461A (ko) * 2003-11-06 2006-11-23 와이어쓰 만성 골수 백혈병(ｃｍｌ)의 치료를 위한4-아닐리노-3-퀴놀린카보니트릴
FR2862301B1 (fr) * 2003-11-17 2007-12-21 Aventis Pharma Sa Nouveau procede de preparation de quinoleines 3-fluorees
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
US20060116375A1 (en) * 2004-10-22 2006-06-01 Wyeth 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury
CN120022370A (zh) 2005-02-03 2025-05-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
CA2608540A1 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
DK1896020T3 (da) 2005-06-17 2014-10-27 Univ Texas SKI 606 som src-kinase-inhibitor til behandling af osteolytiske læsioner
EP1902029B2 (de) 2005-07-01 2022-02-16 Wyeth LLC Kristalline formen von 4-[(2,4-dichlor-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-chinolincarbonsäurenitril und verfahren zu deren herstellung
US20070104721A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
TW200808728A (en) * 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
DK2478905T3 (da) 2007-06-01 2014-06-30 Wyeth Llc Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101602687A (zh) * 2008-06-13 2009-12-16 上海特化医药科技有限公司 6-硝基苯乙酮类化合物、其制备方法及用途
ES2431355T3 (es) 2008-06-17 2013-11-26 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
DK2326329T3 (en) 2008-08-04 2017-02-20 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US20100069340A1 (en) * 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
CN101723854A (zh) 2008-10-24 2010-06-09 上海特化医药科技有限公司 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
EP4218760A3 (de) 2009-04-06 2023-08-16 Wyeth LLC Behandlungsschema mit neratinib für brustkrebs
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
AU2011264209B2 (en) * 2010-06-09 2014-08-07 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Cyanoquinoline derivatives
CN103261186A (zh) 2010-12-13 2013-08-21 诺瓦提斯公司 二聚化iap抑制剂
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
AP2014007400A0 (en) 2011-07-13 2014-01-31 Novartis Ag 4-Piperidinyl compounds for use as tankyrase inhibitors
EP2731951B1 (de) 2011-07-13 2015-08-19 Novartis AG 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d}pyrminidinylverbindungen zur verwendung als tankyrase -inhibitoren
WO2013012723A1 (en) 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
AR092530A1 (es) * 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN103804353A (zh) * 2012-11-01 2014-05-21 常辉 一类治疗精神分裂症的化合物及其用途
EP2956138B1 (de) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutische verbindungen und verwendungen davon
AP2015008618A0 (en) 2013-02-19 2015-07-31 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
EP3763710A1 (de) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutische verbindungen und verwendungen davon
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2014128622A1 (en) 2013-02-21 2014-08-28 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
SG11201506395RA (en) 2013-03-15 2015-09-29 Novartis Ag Antibody drug conjugates
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP6523303B2 (ja) 2014-01-17 2019-05-29 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
EP3094629B1 (de) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idin-derivate und zusammensetzungen davon zur hemmung der aktivität von shp2
EP2980088A1 (de) 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Aminosubstituierte Isothiazole
IN2014CH00840A (de) * 2014-02-20 2015-09-18 Apotex Inc
WO2015149727A1 (en) 2014-04-02 2015-10-08 Zentiva, K.S. Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US10238748B2 (en) 2014-08-12 2019-03-26 Novartis Ag Anti-CDH6 antibody drug conjugates
EP3191126B1 (de) 2014-09-13 2020-05-13 Novartis AG Kombinationstherapien aus alk-hemmern
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
JP6815992B2 (ja) 2014-10-08 2021-01-20 ノバルティス アーゲー キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
CN104311485B (zh) * 2014-10-13 2016-08-24 烟台市华文欣欣医药科技有限公司 一种治疗白血病的药物博舒替尼的制备方法
AU2015347015B2 (en) 2014-11-14 2019-02-14 Novartis Ag Antibody drug conjugates
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EP3789027A1 (de) 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib zur prävention und/oder behandlung von amyotropher lateralsklerose
AU2016238436A1 (en) 2015-03-25 2017-08-17 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
CN105085398A (zh) * 2015-09-06 2015-11-25 合肥华方医药科技有限公司 一种博舒替尼异构体杂质的制备方法
EP3368092B9 (de) 2015-10-29 2020-07-29 Novartis AG Antikörperkonjugate mit toll-like-rezeptoragonist
JP6969800B2 (ja) 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
RU2021106500A (ru) 2016-06-14 2021-04-16 Новартис Аг Соединения и композиции для подавления активности shp2
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (de) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Kristalline formen von therapeutischen verbindungen und verwendungen davon
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US11179413B2 (en) 2017-03-06 2021-11-23 Novartis Ag Methods of treatment of cancer with reduced UBB expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
JP7791642B2 (ja) 2017-05-24 2025-12-24 ノバルティス アーゲー 抗体－サイトカイングラフト化タンパク質及び癌の治療における使用方法
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
CN111201223B (zh) 2017-09-11 2024-07-09 克鲁松制药公司 SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
ES2963694T3 (es) 2018-07-10 2024-04-01 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2)
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
DK4545100T3 (da) 2018-07-25 2026-02-23 Advanced Accelerator Applications S A Stabile koncentrerede radionuklidkompleksopløsninger
BR112021005082A2 (pt) 2018-09-18 2021-06-08 Nikang Therapeutics, Inc. derivados de anel tricíclico fundido como inibidores de src homologia-2 fosfatase
EP3856349A1 (de) 2018-09-25 2021-08-04 Black Diamond Therapeutics, Inc. Tyrosinkinase-inhibitorzusammensetzungen, verfahren zu ihrer herstellung und ihre verwendung
SG11202102981SA (en) 2018-09-25 2021-04-29 Black Diamond Therapeutics Inc Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN112867512A (zh) 2018-09-25 2021-05-28 意大利国际先进加速器应用有限公司 联合疗法
WO2020065453A1 (en) 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
EP3873532A1 (de) 2018-10-31 2021-09-08 Novartis AG Dc-sign-antikörper-arzneimittelkonjugate
IL282735B2 (en) 2018-11-01 2025-10-01 Gracell Biotechnologies Shanghai Co Ltd Preparations and methods for engineering T cells
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113195541B (zh) 2018-12-21 2024-08-30 诺华股份有限公司 针对pmel17的抗体及其缀合物
AU2020222345B2 (en) 2019-02-15 2022-11-17 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
JP2022542437A (ja) 2019-08-02 2022-10-03 ランティオペプ ベスローテン ヴェンノーツハップ 癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト
CA3150701A1 (en) 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CN114630825B (zh) 2019-11-01 2025-05-16 先正达农作物保护股份公司 杀有害生物活性的稠合二环杂芳香族化合物
JP7805928B2 (ja) 2019-11-26 2026-01-26 ノバルティス アーゲー Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
CN115052662A (zh) 2019-12-20 2022-09-13 诺华股份有限公司 抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022140472A1 (en) 2020-12-22 2022-06-30 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4323349A1 (de) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinonamidverbindungen zur behandlung von krankheiten im zusammenhang mit gspt1
WO2022219407A1 (en) 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Isoindolinone compounds
JP2024517409A (ja) 2021-04-16 2024-04-22 ノバルティス アーゲー 抗体薬物結合体及びその作成方法
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
EP4359408A1 (de) 2021-06-24 2024-05-01 Syngenta Crop Protection AG 2-[3-[1 [(chinazolin-4-yl)amino!ethyl!pyrazin-2-yl!thiazole-5-carbonitrile derivate und ähnliche verbindungen als schädlingsbekämpfungsmittel
CN117980310A (zh) 2021-07-14 2024-05-03 尼坎治疗公司 作为kras抑制剂的亚烷基衍生物
EP4499634A1 (de) 2022-03-28 2025-02-05 Nikang Therapeutics, Inc. Sulfonamidderivate als cyclinabhängige kinase-2-hemmer
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
EP4536363A1 (de) 2022-06-08 2025-04-16 Nikang Therapeutics, Inc. Sulfamidderivate als cyclinabhängige kinase-2-hemmer
CN119421880A (zh) 2022-06-21 2025-02-11 先正达农作物保护股份公司 杀有害生物活性的稠合二环杂芳香族化合物
JP2025524064A (ja) 2022-07-26 2025-07-25 ノバルティス アーゲー Ａｋｒ１ｃ３依存性ｋａｒｓ阻害剤の結晶形態
CN115286573B (zh) * 2022-08-04 2024-12-10 常州工程职业技术学院 一种1-烷氧基异喹啉化合物的绿色合成方法
EP4615833A1 (de) 2022-11-11 2025-09-17 Nikang Therapeutics, Inc. Bifunktionelle verbindungen mit 2,5-substituierten pyrimidinderivaten zum abbau von cyclinabhängiger kinase 2 über ubiquitin-proteasom-signalweg
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025072462A1 (en) 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2025117616A1 (en) 2023-11-27 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025117981A1 (en) 2023-12-02 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2025212828A1 (en) 2024-04-03 2025-10-09 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025240536A1 (en) 2024-05-15 2025-11-20 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
ZA9756B (en) * 1996-01-16 1997-07-17 Warner Lambert Co Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
KR100736502B1 (ko) 1998-09-29 2007-07-06 와이어쓰 홀딩스 코포레이션 단백질 티로신 키나제 억제제로서 치환된 3-시아노퀴놀린
US6638929B2 (en) * 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
DE10017539A1 (de) 2000-04-08 2001-10-11 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ATE341545T1 (de) * 2001-07-16 2006-10-15 Astrazeneca Ab Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase

Also Published As

Publication number Publication date
SI1499594T1 (sl) 2005-12-31
AR039776A1 (es) 2005-03-02
US6780996B2 (en) 2004-08-24
EP1499594A1 (de) 2005-01-26
AU2003231162A1 (en) 2003-11-17
US20030212276A1 (en) 2003-11-13
TW200306831A (en) 2003-12-01
UA77799C2 (en) 2007-01-15
CO5631435A2 (es) 2006-04-28
CN1665787A (zh) 2005-09-07
WO2003093241A1 (en) 2003-11-13
DE60301350D1 (de) 2005-09-22
RU2309149C2 (ru) 2007-10-27
NO20044533D0 (no) 2004-10-21
IL164851A0 (en) 2005-12-18
JP2005529907A (ja) 2005-10-06
CN100354263C (zh) 2007-12-12
NO20044533L (no) 2004-11-29
DK1499594T3 (da) 2005-10-17
ES2243903T3 (es) 2005-12-01
DE60301350T2 (de) 2006-03-23
HK1070358A1 (en) 2005-06-17
TWI275390B (en) 2007-03-11
ECSP045406A (es) 2005-01-03
CA2483529A1 (en) 2003-11-13
BR0309712A (pt) 2005-02-15
MXPA04010664A (es) 2005-01-25
KR20040106420A (ko) 2004-12-17
AU2003231162B2 (en) 2009-08-06
EP1499594B1 (de) 2005-08-17
RU2004134735A (ru) 2005-06-10
NZ536141A (en) 2006-03-31
ZA200409639B (en) 2006-06-28
CR7511A (es) 2006-02-06

Similar Documents

Publication Publication Date Title
ATE302191T1 (de) Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile
DE60206472D1 (de) Verfahren und vorrichtung zur herstellung von mineralwolle
DE50006193D1 (de) Verfahren zur herstellung von otoplastiken und otoplastik
DE602004020476D1 (de) Verfahren zur herstellung von thermoplastischen vulkanisaten und thermoplastischen vulkanisaten
DE60333660D1 (de) Verfahren und gerät zur herstellung von saugfähigen einweg-artikeln
ATE403641T1 (de) Verfahren zur herstellung von o- desmethylvenlafaxin
DE60217860D1 (de) Verfahren zur herstellung von haftverschlüssen
DE60326628D1 (de) Dorn und verfahren zur herstellung von stents
ATE330020T1 (de) Verfahren zur herstellung von dihydroxyestern und ihren derivaten
ATE324794T1 (de) Haustierfutter und verfahren zur herstellung
ATE338619T1 (de) Verfahren und vorrichtung zur herstellung von borsten
ATA11912002A (de) Verfahren zur herstellung von fälschungssicheren identifikationsmerkmalen
DE60230908D1 (de) Verfahren zur herstellung von polyarylenethern
ATE433441T1 (de) Verfahren und vorrichtung zur herstellung von percarbonsäure
DE60200836D1 (de) Verfahren zur herstellung von kunststoffteilanordnungen
DE50312128D1 (de) Lenkung und Verfahren zur Lenkung
DE60311292D1 (de) Verfahren zur herstellung von polyurethangegenständen und vorrichtung dafür
ATE297430T1 (de) Verfahren zur herstellung von tannin und seine verwendung
DE10242955B4 (de) Kunststoffaß und Verfahren zur Herstellung des Fasses
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
ATE399764T1 (de) Verfahren zur herstellung von bisepoxiden und dithiolen
ATE360610T1 (de) Verfahren zur herstellung von cilastatin
ATE441662T1 (de) Verfahren zur herstellung von echinocandinderivaten
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
ATE406372T1 (de) Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1499594

Country of ref document: EP

REN Ceased due to non-payment of the annual fee